Drug intelligence / Profile preview

TachoComb + enoxaparin

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Topical, Subcutaneous

Overview

TachoComb + enoxaparin is a combination therapy used in surgical settings. TachoComb is a local hemostyptic agent used to seal the mediastinum and prevent bleeding after surgical procedures, while enoxaparin is a low molecular weight heparin anticoagulant used for thromboembolic prophylaxis. This combination has been studied in patients undergoing surgical resection with complete mediastinal lymph node dissection for non-small cell lung cancer, where it demonstrated significantly lower cumulative chest drain volumes and earlier chest tube removal compared to other combinations of hemostatic agents and anticoagulants.

Brand names: TachoComb + Lovenox

Targets

ATIII (Antithrombin III)F10 (Factor Xa)

Beyond the preview

Go deeper on TachoComb + enoxaparin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TachoComb + enoxaparin.

Explore the full profile